NexGel shares surge 20.90% intraday after announcing $15M upfront payment and up to $20M in milestones for Celularity's regenerative biomaterial portfolio, expected to triple revenue and make the company immediately profitable.

NexGel surged 20.90% intraday after announcing the financial terms of its agreement to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity. The deal includes a $15 million upfront cash payment and up to $20 million in milestone payments tied to net sales, with the transaction expected to approximately triple NexGel’s annual revenue to $35 million and make the company immediately profitable upon closing. The portfolio, focused on tendon repair, skin grafts, and bone growth, includes products with established clinical use and reimbursement pathways, while also expanding NexGel’s capabilities through an experienced commercial team. The announcement aligns with NexGel’s strategic pivot to capitalize on the regenerative biomaterials market, positioning the deal as a transformative milestone.